Updated: FDA punts PDUFA date for another indication for AstraZeneca, Merck's cancer drug Lynparza
The FDA says not yet to two Big Pharmas on their collaborative PARP inhibitor’s newest indication — it needs three more months to review.
AstraZeneca and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
